Innoscape

Topics: Pharma-innovations, Disruptive Technologies

Our analysis of scientific AI-pharma papers allowed us to gain quantitative insights into general industry trends, country and regional comparisons, valuations of leading pharmaceutical companies, as well as detailed looks at Basel heavyweights Novartis and Roche.

Remarkably, Europe is doing really well, especially the life sciences in Switzerland! The following slides summarize our findings.

Topic: Disruptive Technologies

Despite tremendous growth in the volume of new scientific and technological knowledge, the popular press has recently raised concerns that disruptive innovation is slowing. These dire prognoses were driven in part by Park et al. (2023), a Nature publication that uses decades of data and millions of observations coupled with a novel quantitative metric (the CD index) that characterizes innovation in science and technology as either consolidating or disruptive. We challenge the Park et al. (2023) patent findings, principally around concerns of truncation bias and exclusion bias. Read more in our article published in the journal Research Policy.

Topic: R&D collaborations

One third of current Swiss scientific publications are joint work with scientists from the EU. Not surprisingly, Switzerland’s non-association to the EU's new Horizon Europe research program poses challenges for the Swiss research community, its economy and society as a whole. We shed light on the role of the predecessor program Horizon 2020 in promoting Swiss-European scientific partnerships to highlight the potential consequences of this non-association.